Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BeneFIX

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
ObjectivesTo develop a recombinant human factor IX (rFIX) formulation equivalent to commercially available products in terms of… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
2017
2017
Dear Sir, Factor VIII and IX products with enhanced half-life are being introduced into routine clinical practice1. Not… Expand
2016
2016
FIX binds tightly to collagen IV. Furthermore, a FIX mutant, FIXK5R, which binds better than wild-type FIX to collagen IV… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2015
2015
  • S. G. Desai
  • Journal of biotechnology
  • 2015
  • Corpus ID: 31108952
Recombinant clotting factors are important biotherapeutics that Pfizer has produced and marketed for over fifteen years. Owing to… Expand
Highly Cited
2014
Highly Cited
2014
Due to variability in the one-stage clotting assay, the performance of new factor IX (FIX) products should be assessed in this… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2013
2013
Head‐on comparative studies of factor IX (FIX) concentrates performed under standardized conditions are rarely conducted… Expand
2011
2011
Abstract 2266 Recombinant Factor IX Fc fusion (rFIXFc) was designed to be a long-lasting version of recombinant FIX that has the… Expand
Highly Cited
2007
Highly Cited
2007
Summary.   BeneFix®, the only recombinant factor IX (FIX), has been reformulated. The reformulation involves a change in diluent… Expand
2001
2001
The safety and efficacy of adjusted continuous infusion (CI) of recombinant factor IX (FIX; BeneFix®) was assessed in vitro and… Expand
1999
1999
The effects of a recombinant factor IX product (BeneFix), and of five plasma‐derived factor IX products, AlphaNine, Immunine… Expand